Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HOOK NASDAQ:SLGL NASDAQ:VBIV NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOOKHOOKIPA Pharma$1.18-0.4%$1.10$0.81▼$1.77$14.55M0.8411,224 shs14,586 shsSLGLSol-Gel Technologies$70.86+1.9%$78.52$6.80▼$97.97$195.40M1.1638,069 shs11,289 shsVBIVVBI Vaccines$0.07$0.23$0.06▼$1.35$1.87M2.183.66 million shsN/AWVEWAVE Life Sciences$7.18-0.8%$9.65$5.02▼$21.73$1.39B-1.324.08 million shs2.55 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOOKHOOKIPA Pharma0.00%+1.28%+5.80%+12.86%-26.40%SLGLSol-Gel Technologies0.00%-6.08%-6.66%+5.72%+800.78%VBIVVBI Vaccines0.00%0.00%0.00%0.00%0.00%WVEWAVE Life Sciences0.00%+2.55%+1.97%-46.17%+11.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOOKHOOKIPA Pharma$1.18-0.4%$1.10$0.81▼$1.77$14.55M0.8411,224 shs14,586 shsSLGLSol-Gel Technologies$70.86+1.9%$78.52$6.80▼$97.97$195.40M1.1638,069 shs11,289 shsVBIVVBI Vaccines$0.07$0.23$0.06▼$1.35$1.87M2.183.66 million shsN/AWVEWAVE Life Sciences$7.18-0.8%$9.65$5.02▼$21.73$1.39B-1.324.08 million shs2.55 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOOKHOOKIPA Pharma0.00%+1.28%+5.80%+12.86%-26.40%SLGLSol-Gel Technologies0.00%-6.08%-6.66%+5.72%+800.78%VBIVVBI Vaccines0.00%0.00%0.00%0.00%0.00%WVEWAVE Life Sciences0.00%+2.55%+1.97%-46.17%+11.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOOKHOOKIPA Pharma 0.00N/AN/AN/ASLGLSol-Gel Technologies 2.33Hold$110.0055.24% UpsideVBIVVBI Vaccines 0.00N/AN/AN/AWVEWAVE Life Sciences 2.87Moderate Buy$27.50283.01% UpsideCurrent Analyst Ratings BreakdownLatest HOOK, VBIV, SLGL, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026WVEWAVE Life Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $24.004/30/2026WVEWAVE Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.004/29/2026WVEWAVE Life Sciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.00 ➝ $15.004/24/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/20/2026WVEWAVE Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026WVEWAVE Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $18.003/27/2026WVEWAVE Life Sciences Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $21.003/27/2026WVEWAVE Life Sciences Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$27.00 ➝ $13.003/25/2026WVEWAVE Life Sciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/25/2026WVEWAVE Life Sciences MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$22.00 ➝ $27.003/10/2026WVEWAVE Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$43.00 ➝ $52.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOOKHOOKIPA Pharma$9.35M1.56N/AN/A$4.25 per share0.28SLGLSol-Gel Technologies$19.39M10.27N/AN/A$8.19 per share8.65VBIVVBI Vaccines$9.41M0.20N/AN/A$0.32 per share0.20WVEWAVE Life Sciences$42.73M32.33N/AN/A$2.66 per share2.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOOKHOOKIPA Pharma-$43.50M-$3.54N/AN/AN/A-785.66%-120.09%-77.14%N/ASLGLSol-Gel Technologies-$6.13M-$2.23N/AN/AN/A-31.60%-24.29%-18.73%5/22/2026 (Estimated)VBIVVBI Vaccines-$92.84MN/AN/AN/AN/A-881.79%-525.42%-45.87%N/AWVEWAVE Life Sciences-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%N/ALatest HOOK, VBIV, SLGL, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026SLGLSol-Gel Technologies-$1.84N/AN/AN/A$0.90 millionN/A4/29/2026Q1 2026WVEWAVE Life Sciences-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 million3/19/2026Q4 2025SLGLSol-Gel Technologies$0.39-$1.07-$1.46-$1.06$6.50 million$0.70 million2/26/2026Q4 2025WVEWAVE Life Sciences-$0.28-$0.30-$0.02-$0.30$15.68 million$17.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHOOKHOOKIPA PharmaN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/AVBIVVBI VaccinesN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOOKHOOKIPA PharmaN/A3.613.61SLGLSol-Gel TechnologiesN/A4.374.37VBIVVBI VaccinesN/A0.340.21WVEWAVE Life SciencesN/A11.2611.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOOKHOOKIPA Pharma63.88%SLGLSol-Gel Technologies26.18%VBIVVBI Vaccines12.26%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipHOOKHOOKIPA Pharma3.30%SLGLSol-Gel Technologies66.51%VBIVVBI Vaccines10.35%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHOOKHOOKIPA Pharma16012.33 million11.79 millionOptionableSLGLSol-Gel Technologies502.81 million941,000No DataVBIVVBI Vaccines2228.68 million25.71 millionNo DataWVEWAVE Life Sciences240192.38 million146.25 millionOptionableHOOK, VBIV, SLGL, and WVE HeadlinesRecent News About These CompaniesGrowth Investors: Industry Analysts Just Upgraded Their Wave Life Sciences Ltd. (NASDAQ:WVE) Revenue Forecasts By 91%May 8 at 5:29 PM | finance.yahoo.comWave Life Sciences: Good Platform, Mixed Clinical Trial Data, HoldMay 7 at 11:02 AM | seekingalpha.comHC Wainwright Has Bullish Forecast for WVE Q2 EarningsMay 4, 2026 | americanbankingnews.comHC Wainwright Expects Higher Earnings for WAVE Life SciencesMay 4, 2026 | marketbeat.comCanaccord Genuity Reaffirms Their Buy Rating on Wave Life Sciences (WVE)May 3, 2026 | theglobeandmail.comA Look At Wave Life Sciences (WVE) Valuation After Sharp Year To Date Share Price DeclineMay 3, 2026 | finance.yahoo.comPictet Asset Management Holding SA Purchases 790,175 Shares of WAVE Life Sciences Ltd. $WVEMay 2, 2026 | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for WAVE Life Sciences (NASDAQ:WVE) Stock PriceMay 2, 2026 | americanbankingnews.comWAVE Life Sciences (NASDAQ:WVE) Upgraded to "Hold" at Wall Street ZenMay 2, 2026 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 2, 2026 | americanbankingnews.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by AnalystsMay 2, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Given New $43.00 Price Target at Canaccord Genuity GroupApril 30, 2026 | marketbeat.comWAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...April 29, 2026 | finance.yahoo.comWAVE Life Sciences (NASDAQ:WVE) Shares Down 7.6% - Here's What HappenedApril 29, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPSApril 29, 2026 | marketbeat.comWAVE Life Sciences Q1 Earnings Call HighlightsApril 28, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading 5.5% Higher - Time to Buy?April 28, 2026 | marketbeat.comWave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue EstimatesApril 28, 2026 | zacks.comWave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 28, 2026 | globenewswire.comWAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Should You Sell?April 24, 2026 | marketbeat.comWAVE Life Sciences (WVE) Projected to Post Earnings on TuesdayApril 24, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOOK, VBIV, SLGL, and WVE Company DescriptionsHOOKIPA Pharma NASDAQ:HOOK$1.18 -0.01 (-0.42%) As of 05/8/2026 03:25 PM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Sol-Gel Technologies NASDAQ:SLGL$70.86 +1.32 (+1.90%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$70.42 -0.44 (-0.61%) As of 05/8/2026 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.VBI Vaccines NASDAQ:VBIVVBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.WAVE Life Sciences NASDAQ:WVE$7.18 -0.06 (-0.83%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$7.24 +0.07 (+0.91%) As of 05/8/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
